← Product Code [OSD](/productcode/OSD) · K250419

# Intimate Rose Pelvic Wand (Purple); Intimate Rose Bendable Pelvic Wand (Orange); Intimate Rose Temperature Pelvic Wand (Yellow) (K250419)

_Plus EV Holdings, Inc. D/B/A Intimate Rose · OSD · Jul 27, 2026 · Physical Medicine · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K250419

## Device Facts

- **Applicant:** Plus EV Holdings, Inc. D/B/A Intimate Rose
- **Product Code:** [OSD](/productcode/OSD.md)
- **Decision Date:** Jul 27, 2026
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 890.5670
- **Device Class:** Class 2
- **Review Panel:** Physical Medicine

## Regulatory Identification

A hand-held internal therapeutic massager device is a prescription device intended for medical purposes to manually provide direct pressure applied to localized areas of pain or tenderness in the myofascial tissue associated with chronic pelvic pain syndromes. The device is inserted rectally or vaginally and provides quantitative feedback to the user of the applied force to the target tissue.

## Special Controls

In combination with the general controls of the FD&C Act, the AHIP Internal Trigger Point Wand is subject to the following special controls:

- 1. The labeling must include adequate directions for use, including prescribing information, to ensure safe and effective use by the patient;
- 2. Appropriate analysis/testing must validate electromagnetic compatibility (EMC), electrical safety and mechanical safety;
- 3. Non-clinical performance testing must demonstrate a reasonable assurance of safety and effectiveness. including mechanical durability and accurate feedback mechanism:
- 4. Appropriate software verification, validation, and hazard analysis must be performed: and
- 5. All elements of the device that may contact the patient must be demonstrated to be biocompatible.

*Classification.* Class II (special controls). The device, when it is for prescription use only with a quantitative feedback mechanism and a disposable covering, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 890.9. The special controls for this device are:(1) Labeling must include adequate directions for use.
(2) Non-clinical performance testing must demonstrate electromagnetic compatibility (EMC), electrical safety and mechanical safety.
(3) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Mechanical durability; and
(ii) Accuracy of the feedback mechanism.
(4) Software verification, validation, and hazard analysis must be performed.
(5) The patient-contacting components of the device must be demonstrated to be biocompatible.

---

**Source:** [https://fda.innolitics.com/device/K250419](https://fda.innolitics.com/device/K250419)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com